certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
=== P53 and p73 === p53 and p73 are tumor suppressor proteins and their degradation is tightly regulated by ubiquitination. Recently it was shown that their degradation can also occur via an ubiquitin-independent process; NQO1 blocks p53 and p73 degradation in the presence of NADH and protects them from 20S proteasomal degradation. This protein-protein interaction between p53 and NQO1 was non-catalytic.
== Plot == Fifteen-year-old orphan Jolene breaks free from foster care, marrying Mickey, a nerdy 20-year-old. They live with Mickey's Uncle Phil and Aunt Kay. On the night before her sixteenth birthday, Jolene asks Mickey about his mother, but he rebuffs her and starts crying. To make him feel better, she seduces him, but Mickey's inexperience leads to uncomfortable and joyless sex. The next day, Mickey and Uncle Phil wish Jolene "Happy Birthday" with Kay asking Jolene to clean the floor. Phil walks in and is aroused by Jolene's dancing while cleaning the floor and they have sex. They start a passionate affair, and Phil promises to build a house for the two of them, but asks Jolene to keep their relationship a secret, due to them both being married. Upon catching Phil and Jolene in bed, Kay kicks Jolene out of the house. After a physical altercation with Phil, Mickey drives off and kills himself by jumping off a bridge. Aunt Kay has Jolene placed in a juvenile mental institution, where she meets Cindy, a psychiatric nurse. Jolene, a talented artist, asks for paper and colored pencils to draw. Her request is denied, but she is allowed crayons, and she starts a small business selling crayon portraits to her fellow patients. Jolene is called to testify against Uncle Phil, and he is sentenced to eighteen months in prison for statutory rape. Cindy, a closeted lesbian, is immediately infatuated with Jolene and this culminates in another affair. Cindy breaks Jolene out of the mental hospital and hides her in her apartment.
According to Thomas Molloy, writing in the Irish Independent, "It had no qualms about selling drink to Catholics but it did everything it could to avoid employing them until the 1960s." Guinness thought they brewed their last porter in 1973. In the 1970s, following declining sales, the decision was taken to make Guinness Extra Stout more "drinkable". The gravity was subsequently reduced, and the brand was relaunched in 1981. Pale malt was used for the first time, and isomerised hop extract began to be used. In 2014, two new porters were introduced: West Indies Porter and Dublin Porter. Guinness acquired The Distillers Company in 1986. This led to a scandal and criminal trial concerning the artificial inflation of the Guinness share price during the takeover bid engineered by the chairman, Ernest Saunders. A subsequent £5.2 million success fee paid to an American lawyer and Guinness director, Tom Ward, was the subject of the case Guinness plc v Saunders, in which the House of Lords declared that the payment had been invalid. In the 1980s, as the IRA's bombing campaign spread to London and the rest of Britain, Guinness considered scrapping the harp as its logo. In 1997 the company merged with Grand Metropolitan to form Diageo. The company was maintained as a separate entity within Diageo and has retained the rights to the product and all associated trademarks of Guinness.
== Development == The basis of GoldSrc is the engine used in the video game Quake, albeit with heavy modification by Valve. While the engine served as the basis for GoldSrc, Gabe Newell said that a majority of the code used in the engine was created by Valve. GoldSrc's artificial intelligence systems, for example, were essentially made from scratch. The engine also uses some code from other games in the Quake series, including QuakeWorld and Quake II. In 1997, Valve hired Ben Morris and acquired Worldcraft, a tool for creating custom Quake maps. The tool was renamed Valve Hammer Editor and became the official mapping tool for GoldSrc. The engine supports skeletal animation, which allowed for more realistic body kinematics and facial expression animations than most other engines at the time of release. The GoldSrc engine initially had no real name and was simply called the Half-Life engine. When the need arose for Valve to work on the engine without risking introducing bugs into Half-Life's codebase, Valve forked the code, creating two main engine branches: one gold master branch, "GoldSrc", and the other "Src". Internally, any games using the original branch were referred to as "Goldsource" to differentiate it from the second branch, while the "Src" branch evolved into the Source engine. Valve released versions of the GoldSrc engine for OS X and Linux in 2013, eventually porting all of their first-party games using the engine to the platforms by the end of the year.
Cytokinins (CKs) are a group of chemicals that influence cell division and shoot formation. They also help delay senescence of tissues, are responsible for mediating auxin transport throughout the plant, and affect internodal length and leaf growth. They were called kinins in the past when they were first isolated from yeast cells. Cytokinins and auxins often work together, and the ratios of these two groups of plant hormones affect most major growth periods during a plant's lifetime. Cytokinins counter the apical dominance induced by auxins; in conjunction with ethylene, they promote abscission of leaves, flower parts, and fruits. Among the plant hormones, the three that are known to help with immunological interactions are ethylene (ET), salicylates (SA), and jasmonates (JA), however more research has gone into identifying the role that cytokinins play in this. Evidence suggests that cytokinins delay the interactions with pathogens, showing signs that they could induce resistance toward these pathogenic bacteria. Accordingly, there are higher CK levels in plants that have increased resistance to pathogens compared to those which are more susceptible. For example, pathogen resistance involving cytokinins was tested using the Arabidopsis species by treating them with naturally occurring CK (trans-zeatin) to see their response to the bacteria Pseudomonas syringa. Tobacco studies reveal that over expression of CK inducing IPT genes yields increased resistance whereas over expression of CK oxidase yields increased susceptibility to pathogen, namely P. syringae.
Sources: en.wikipedia.org
== External links == Roda, A. (2005). "Toward Multianalyte Immunoassays: A Flow-Assisted, Solid-Phase Format with Chemiluminescence Detection". Clinical Chemistry. 51 (10): 1993–1995. doi:10.1373/clinchem.2005.053108. ISSN 0009-9147. PMID 16299900.
Healing of a flap maintains the same process as healing of any wound. There are four stages: hemostasis, inflammation, proliferation, and remodeling, all of which can take up to a year to complete. Following flap surgery, the biggest risk in recovery is flap death. Flap failure is an uncommon occurrence but does happen. The reported flap failure rate in free flaps is less than 5%. This is most commonly caused by venous insufficiency; this accounts for of 54% of all failures. Venous insufficiency is commonly caused by a venous thrombus within the first 2 days following surgery. After the immediate postoperative risk, the flap will continue to heal, adhering to the stages of normal wound healing. It can take over 3 months for an incision to be at 80% tensile strength compared to normal tissue.
== External links == "BRENDA". Archived from the original on 1 April 2022., Database of enzymes giving lists of known inhibitors for each entry "PubChem". National Center for Biotechnology Information. National Library of Medicine. Database of drugs and enzyme inhibitors "Symbolism and Terminology in Enzyme Kinetics". Archived from the original on 20 June 2006. Recommendations of the Nomenclature Committee of the International Union of Biochemistry (NC-IUB) on enzyme inhibition terminology
== Overview == The series focuses on Olivia Pope and her crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington D.C. as political scandals occur and they must try to deal with them.
Sources: en.wikipedia.org
Roseanne Conner (née Harris) is played by Roseanne Barr. Roseanne, in a takeoff of her stand-up comedic and presumed real-life persona, is a bossy, loud, caustic, overweight, and dominant woman. She is also portrayed as smart, resourceful, and witty. She strives to control the lives of her sister, husband, children, co-workers, and friends. Despite a domineering nature, Roseanne is depicted as being a loving wife and mother who works hard and makes as much time for her husband and children as possible. She and her younger sister, Jackie, are the daughters of Beverly and Al Harris. Roseanne is married to Dan Conner and when the series begins they have three young children: Becky, Darlene, and David Jacob ("D.J."); a fourth child, Jerry Garcia, is born in the eighth season of the series. Roseanne and Dan mostly live paycheck-to-paycheck, raising a family amid the many hardships of poverty, obesity, and domestic troubles with love and humor. Roseanne works at the Wellman Plastics factory at the beginning of the show's run and quits after a conflict with her overbearing boss, Mr. Faber; she leads a walkout that includes Jackie and other co-workers. She is intermittently unemployed and holds jobs as a fast-food restaurant employee, a telemarketer, a bartender, and a shampooer/hair sweeper/receptionist at a beauty salon. Subsequently, she works for several years as a waitress in the luncheonette at Rodbell's department store located in the Lanford Mall (much to the chagrin of her daughters Becky and Darlene, who regularly hang out there).
== Selected recent publications == Biggar, K.K., and Storey, K.B. Functional impact of non-coding RNA regulation in extreme stress adaptation. J. Mol. Cell. Biol. In Press. doi.org/10.1093/jmcb/mjx053 Biggar, K.K., Wang Z. and Li, S. SnapShot: Lysine methylation beyond histones. Mol. Cell 68(5):1016–1016.e1. Invited submission Singal, S.S., Nygard, K.*, Biggar, K.K.*, Shehab, M.A., S.S.C. Li, Jansson, T. and Gupta, M.B. Interaction between IGFBP-1, protein kinase CSNK-2 and mTOR in HepG2 cells as demonstrated by dual immunofluorescence and in situ PLA. Am. J. Pathol. In press, doi.org/10.1016/j.ajpath.2017.09.009 Biggar, K.K., Dawson, N.J. and Storey, K.B. Native protein denaturation using urea. Biotechniques 62(1): xiii (epub) Shehab, M.A., Biggar, K.K., Singal, S.S., Nygard, K., Li, S.S.C., Jansson, T. and Gupta, M.B. Exposure of decidualized HESC to low oxygen tension and leucine deprivation results in increased IGFBP-1 phosphorylation and reduced IGF-I bioactivity. Mol. Cell. Endo. 452:1-14 Wu, Z., Connolly, J. and Biggar, K.K. Beyond histones: The expanding roles of lysine methylation. FEBS J. 284(17): 2732-2744 Biggar, K.K. and Storey, K.B. Exploration of low temperature microRNA function in an anoxia tolerant vertebrate ectotherm, the red eared slider turtle (Trachemys scripta elegans). J. Thermal Biol. In Press Wu, C.W., Biggar, K.K., Luu, B.E., Szereszewski, K.E. and Storey, K.B. Analysis of microRNA expression during the torpor-arousal cycle of a mammalian hibernator, the 13-lined ground squirrel. Physiol. Genomics DOI: 10.1152/physiolgenomics.00005.2016
== Infections == Smoking is also linked to susceptibility to infectious diseases, particularly in the lungs (pneumonia). Smoking more than 20 cigarettes a day increases the risk of tuberculosis by two to four times and being a current smoker has been linked to a fourfold increase in the risk of invasive disease caused by the pathogenic bacteria Streptococcus pneumoniae. It is believed that smoking increases the risk of these and other pulmonary and respiratory tract infections both through structural damage and through effects on the immune system. The effects on the immune system include an increase in CD4+ cell production attributable to nicotine, which has tentatively been linked to increased HIV susceptibility. Smoking increases the risk of Kaposi's sarcoma in people without HIV infection. One study found this only with the male population and could not draw any conclusions for the female participants in the study.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.